Purdue's abuse-resistant OxyContin approved in US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Purdue Pharma's reformulation of OxyContin (oxycodone HCl controlled-release 10mg, 15mg, 20mg, 30mg, 40mg, 60mg and 80mg tablets) that has been designed to be less susceptible to misuse and abuse. It is indicated for the management of moderate-to-severe pain where a continuous, around–the-clock opioid analgesic is needed for an extended period of time.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.